Efficacy and Safety of One Single Dose of SR58611 Compared to Placebo and Paroxetine

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2003
Primary objective is to demonstrate the antidepressant efficacy on the Hamilton depression rating scale (HAM-D) of amibegron (SR58611) 700 mg/day compared to placebo in the treatment of patients with a recurrent major depressive episode (MDD). Secondary objective is to assess the safety profile of amibegron 700 mg/d in comparison to placebo and to assess plasma concentrations of the active metabolite.
Epistemonikos ID: 03f60ef8bf4a1b4f4f65572c03a69d9403204f32
First added on: May 05, 2024